Stephen M. Ansell, MD, PhD

Articles

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

September 25th 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Dr. Ansell on the Development of Potential Immune-Harnessing Therapeutics in Lymphoma

September 14th 2023

Stephen M. Ansell, MD, PhD, highlights several emerging therapeutics that have the potential to better harness the immune system in patients with lymphoma subtypes.

Dr. Ansell on the LOTIS-2 Trial of Loncastuximab Tesirine in R/R DLBCL

September 27th 2022

Stephen M. Ansell, MD, PhD, discusses the investigation of loncastuximab tesirine in the phase 2 LOTIS-2 trial in relapsed/refractory diffuse large B-cell lymphoma.

Dr. Ansell on the Evolving Treatment Landscape in DLBCL

March 15th 2022

Stephen M. Ansell, MD, PhD, discusses the evolving treatment landscape in diffuse large B-cell lymphoma.

Dr. Ansell on Incorporating Immunotherapies Beyond CAR T-Cell Therapy in NHL

August 11th 2021

Stephen M. Ansell, MD, PhD, discusses incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Ansell on Challenges With PET Scans in Hodgkin Lymphoma

May 4th 2021

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

Dr. Ansell on the Role of PET Scans in Hodgkin Lymphoma

April 23rd 2021

Stephen M. Ansell, MD, PhD, discusses the role of positron emission tomography scans in patients with Hodgkin lymphoma.

Dr. Ansell Discusses the Role of PD-1 Blockade in Lymphoma

August 20th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.

Dr. Ansell on Strategies to Address Immune Evasion in Lymphoma

August 7th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

Dr. Ansell Discusses Immune Evasion in Lymphoma

July 27th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses immune invasion in lymphoma.

Dr. Ansell on Difficult Challenges in the MCL Landscape

August 15th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses difficult challenges to overcome in the landscape of mantle cell lymphoma (MCL).

Dr. Ansell on Combining CAR T-cell Therapy and Immunotherapy in Lymphomas

August 3rd 2017

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the possibility of blending immunotherapy agents with chimeric antigen receptor (CAR) T-cell therapy across lymphoma populations.

Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

June 22nd 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Dr. Ansell on Promising Combinations Being Studied in MCL

May 17th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Dr. Ansell on Recent Therapeutic Advancements in MCL

May 2nd 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses some of the recent therapeutic advancements that have been reported in the field of mantle cell lymphoma (MCL).

Dr. Ansell on Promise With Immunotherapy in Hodgkin Lymphoma

December 23rd 2016

Stephen M. Ansell, MD, PhD, of Mayo Clinic, discusses studies exploring PD-1 inhibitors in Hodgkin lymphoma, specifically the CheckMate-039 trial.